Si-Bone (Nasdaq:SIBN) this week introduced preliminary fourth-quarter outcomes that exceed the expectations on Wall Avenue.

The Santa Clara, California-based orthopedic system firm expects worldwide income to be within the vary of $31.7-$31.9 million in This fall, representing a 26% progress year-over-year. For the complete 12 months, Si-Bone anticipates worldwide income within the vary of $106.1-$106.3 million for an 18% progress in comparison with FY 2021, in line with a information launch.

The This fall revenues are anticipated to prime the consensus on Wall Avenue, the place analysts are in search of gross sales of $30.31 million.

Si-Bone develops know-how for the surgical remedy of musculoskeletal problems of the sacropelvic anatomy. Its iFuse implant system for minimally invasive surgical procedure of the SI joint has been utilized in greater than 75,000 procedures, in line with the corporate.

Shares in SIBN had been down barely to $15.81 apiece in mid-morning buying and selling right now. MassDevice‘s MedTech 100 Index — which incorporates shares of the world’s largest medical system corporations — rose greater than 8%.